Kontaktujte nás | Jazyk: čeština English
Název: | 12-O-Tetradecanoylphorbol-13-acetate increases cardiomyogenesis through PKC/ERK signaling | ||||||||||
Autor: | Radaszkiewicz, Katarzyna Anna; Beckerová, Deborah; Woloszczuková, Lucie; Radaszkiewicz, Tomasz Witold; Lesáková, Petra; Vondálová Blanářová, Olga; Kubala, Lukáš; Humpolíček, Petr; Pachernik, Jiří | ||||||||||
Typ dokumentu: | Recenzovaný odborný článek (English) | ||||||||||
Zdrojový dok.: | Scientific Reports. 2020, vol. 10, issue 1 | ||||||||||
ISSN: | 2045-2322 (Sherpa/RoMEO, JCR) | ||||||||||
Journal Impact
This chart shows the development of journal-level impact metrics in time
|
|||||||||||
DOI: | https://doi.org/10.1038/s41598-020-73074-4 | ||||||||||
Abstrakt: | 12-O-Tetradecanoylphorbol-13-acetate (TPA) is the most widely used diacylglycerol (DAG) mimetic agent and inducer of protein kinase C (PKC)-mediated cellular response in biomedical studies. TPA has been proposed as a pluripotent cell differentiation factor, but results obtained have been inconsistent. In the present study we show that TPA can be applied as a cardiomyogenesis-promoting factor for the differentiation of mouse embryonic stem (mES) cells in vitro. The mechanism of TPA action is mediated by the induction of extracellular signal-regulated kinase (ERK) activity and the subsequent phosphorylation of GATA4 transcription factor. Interestingly, general mitogens (FGF, EGF, VEGF and serum) or canonical WNT signalling did not mimic the effect of TPA. Moreover, on the basis of our results, we postulate that a TPA-sensitive population of cardiac progenitor cells exists at a certain time point (after days 6–8 of the differentiation protocol) and that the proposed treatment can be used to increase the multiplication of ES cell-derived cardiomyocytes. © 2020, The Author(s). | ||||||||||
Plný text: | https://www.nature.com/articles/s41598-020-73074-4 | ||||||||||
Zobrazit celý záznam |